Study of Zymfentra for people with Crohn's or colitis
Part of Digestive system clinical trials.
This study follows adults with inflammatory bowel disease who are starting or switching to Zymfentra. Researchers will track your health over the next year to see how the medicine works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have Crohn's disease, ulcerative colitis, or unclassified IBD
- You are either starting Zymfentra after your first few infusions of another infliximab, or you are switching from an infliximab you've been taking regularly to Zymfentra
- Your doctor plans to follow you at this center for at least the next 12 months
- Your IBD diagnosis is confirmed by symptoms and tests like a colonoscopy, X-ray, or biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
Hear when a new Indeterminate Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.